iBET has several established collaborations with national and international Pharma companies.
Over the last 20 years, iBET has been developing several projects for international pharmaceutical companies, such as Bayer, Novartis, Merck, Sanofi, Abbvie, Apceth, AstraZeneca, Glaxo-Smith-Kline, Merck & Co., among others.
R&D programs main areas include:
- process development for protein production (including Monoclonal Antibodies);
- production of virus-based vaccines; viral vectors for gene therapy (Retrovirus and Lentivirus, Adenovirus, Adeno Associated Virus and Baculovirus);
- development of tools and methodologies for cell therapy applications and pre-clinical research (novel 3D in vitro models for toxicology and disease models), namely the use of Stem Cells (hESC, Adult Stem Cells and iPS); and
- primary cultures of human hepatocytes, cancer and brain cells.
National Partners

Bial

Medinfar

Tecnimede

GenIbet Biopharmaceuticals

Lecifarma
International Partners

AbbVie, USA

Affilogic, France

Alloksys, The Netherlands

Apceth, Germany

Applied Sensor, Sweden

Aquaporin, Denmark

AstraZeneca, Sweden

Bayer, Germany

Boheringer Ingelheim, Germany

BioReliance, USA

Cellartis-Takara, Sweden

CEVEC, Germany

Crucell, The Netherlands

CSL Behring

Cytiva, Sweden

EMD Millipore, USA

Delta-Vir

Genethon, France

Georg-Speyer-Haus, Germany

Glaxo Smith Kline

Ingenasa, Spain

Janssen Biotech-Johnson & Johnson, USA

Janssen-Cilag GmbH International

Kemin

Lonza, UK

Merck Healthcare KGaA, Germany

Micromet-Amgen, Germany

Novasep, Belgium

Novartis, Switzerland

Novo Nordisk, Denmark

Pall Life Sciences, USA

PBS Biotech, USA

Pharmacelsus, Germany

Polymun, Austria

Redbiotec, Switzerland

Rubius Therapeutics

Sartorius-Stedim, Germany

Sanofi, France

Sumitomo Dainippon Pharma, Japan

TILT Biotherapeutics

Turnstone Biologics

Takeda

UNUM Therapeutics